

An Updated Gene Regulatory Network reconstruction of multidrug-resistant *Pseudomonas aeruginosa* CCBH4851

Márcia da Silva Chagas¹, Fernando Medeiros Filho², Marcelo Trindade dos Santos³, Marcio Argollo de Menezes⁴, Ana Paula D'Alincourt Carvalho-Assef⁵, Fabricio Alves Barbosa da Silva¹

1 Fundação Oswaldo Cruz, Programa de Computação Científica, Rio de Janeiro, RJ, Brazil

2 Fundação Oswaldo Cruz, Instituto Nacional de Infectologia, Laboratório de Pesquisa Clínica em Doenças Febris Agudas, Rio de Janeiro, RJ, Brazil

3 Laboratório Nacional de Computação Científica, Petrópolis, RJ, Brazil

4 Instituto de Física, Universidade Federal Fluminense, Niterói, Brazil

5 Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Laboratório de Pesquisa em Infecção Hospitalar Rio de Janeiro, RJ, Brazil

Correspondence: Márcia da Silva Chagas - chagasmarcia92@gmail.com, Fabricio Alves Barbosa da Silva - fabricio.silva@fiocruz.br

BACKGROUND: Healthcare-associated infections due to multidrug-resistant (MDR) bacteria such as *Pseudomonas aeruginosa* are significant public health issues worldwide. A system biology approach can help understand bacterial behavior and provide novel ways to identify potential therapeutic targets and the development of new drugs. Gene regulatory networks (GRN) are an example of interaction representation *in silico* between regulatory genes and their targets.

OBJECTIVES: In this work, we update the reconstruction of the MDR *P. aeruginosa* CCBH4851 GRN, and analyze and discuss its structural properties.

METHODS: We based this study on the gene orthology inference methodology using the reciprocal best hit method. The *P. aeruginosa* CCBH4851 genome and GRN, published in 2019, and the *P. aeruginosa* PAO1 GRN, published in 2020, were used for this update reconstruction process.

FINDINGS: Our result is a GRN with a larger number of regulatory genes, target genes, and interactions compared to the previous networks, and its structural properties are consistent with the complexity of biological networks and the biological features of *P. aeruginosa*.

MAIN CONCLUSIONS: Here, we present the largest and most complete version of *P. aeruginosa* GRN published to this date, to the best of our knowledge.

Key words: regulatory gene networks, *Pseudomonas aeruginosa*, system biology, computational biology.

INTRODUCTION

Pseudomonas aeruginosa is a ubiquitous and opportunistic pathogen of which infections can affect the lower respiratory tract, skin, urinary tract, eyes, soft tissues, surgical wound, gastrointestinal system, among others, leading to bacteremia, endocarditis, and other complications, particularly in health care settings and in immunocompromised patients.⁽¹⁻³⁾ Moreover, this Gram-negative bacteria is one of the most difficult to treat,⁽⁴⁾ due to its intrinsic resistance, acquisition of resistance through chromosomal gene mutations, and horizontally acquired resistance mechanisms to multiple drugs.⁽³⁾ Multidrug resistance (MDR) imposes the central difficulty in the selection of appropriate antibiotic treatment and reduces treatment options, especially in nosocomial settings such as healthcare-associated infections (HAI).^(5,6)

HAI is a severe public health issue related to high rates of morbidity and mortality in hospitalized patients and excessive healthcare costs.⁽⁷⁾ Worldwide, *P. aeruginosa* is one of the most prevalent agents of HAI.⁽⁸⁾

In Brazil, the Brazilian Health Surveillance Agency ⁽⁹⁾ ranked *P. aeruginosa* as the third most common causative agent of HAI in hospitalized patients in adult

intensive care units (ICU) and the second in pediatric ICU, being nearly 40% of the reported strains resistant to carbapenems ⁽⁹⁾. This class of beta-lactam antibiotic has been widely administered worldwide for treating *P. aeruginosa* infections and other MDR Gram-negative bacterial infections.⁽¹⁰⁾ Indeed, a significantly higher mortality rate was observed among patients infected with MDR *P. aeruginosa* clones (44.6%) compared to those infected with non-MDR (24.8%).⁽⁶⁾

The most epidemiologically important mechanism of carbapenem resistance is the production of carbapenemases. Among MDR *P. aeruginosa* clinical isolates in Brazil, the most prevalent carbapenemase is the São Paulo metallo- β -lactamase (SPM-1).⁽¹¹⁾ This enzyme is encoded by the gene *blaSPM-1*, located on the *P. aeruginosa* chromosome,⁽¹²⁾ and it confers resistance to almost all classes of beta-lactams. The first register of an MDR *P. aeruginosa* strain carrying the *blaSPM-1* gene found in Brazil is from 2003.⁽¹³⁾ Widely disseminated in distinct Brazilian geographic regions, SPM-1-producing *P. aeruginosa* is associated with the clone SP/ST277 and has been isolated from hospital sewage systems, rivers, and microbiota of migratory birds.^(11,12) The strain *P. aeruginosa* CCBH4851, in which this article is based on, belongs to clone SP/ST277, and was involved in an endemic outbreak in Brazil in 2008.⁽¹⁴⁾ This strain is resistant to most antimicrobials of clinical importance, such as aztreonam, amikacin, gentamicin, ceftazidime, cefepime, ciprofloxacin, imipenem, meropenem, and piperacillin-tazobactam, being susceptible only to polymyxin B, and has several mechanisms of mobile genetic elements.^(2, 14)

To better understand *P. aeruginosa*'s behavior, a more comprehensive knowledge of gene expression patterns predicted by the analysis of its gene

regulatory network (GRN) is of great value. A GRN consists of a set of transcription factors (TF) that interact selectively and nonlinearly with each other and with other molecules in the cell to regulate mRNA and protein expression levels.⁽¹⁵⁾

Mathematical modeling and computational simulations are approaches for analyzing the GRN and other complex cellular systems influenced by numerous factors. These models allow the construction of biological networks, predict its behavior under unusual conditions, identify how a disease might develop, and intervene in such development to prohibit cells from reaching undesirable states.⁽¹⁶⁾ In addition, due to their lower cost and high accuracy, such approaches contribute to developing new drugs.⁽¹⁷⁾

The *P. aeruginosa* PAO1 strain had its genome sequence published in 2000, providing information regarding genome size, genetic complexity, and ecological versatility.⁽¹⁸⁾ It has been extensively studied since then.

Published in 2011 by Galán-Vasquez *et al.*,⁽¹⁹⁾ the first *P. aeruginosa* GRN was based on the PAO1 strain (PAO1-2011). In 2019, Medeiros *et al.*⁽²⁾ described a GRN reconstruction of the CCBH4851 strain (CCBH-2019). Finally, in 2020, Galán-Vasquez *et al.*⁽²⁰⁾ published the updated GRN of *P. aeruginosa* with the PAO1 strain (PAO1-2020), which was much larger than the previous ones, containing new interactions. All works analyzed the GRNs main structural properties and regulatory interactions.

This manuscript describes (CCBH-2022), an updated GRN of the MDR *P. aeruginosa* based on the CCBH4851 strain, using as references both CCBH-2019 and PAO1-2020. We characterize regulators, target genes (TGs),

transcription factors (TFs), auto-activation interactions and influential genes of the network.

We analyze the main structural properties of the network, such as degree distribution, clustering coefficient and relative abundance of network motifs. We compare results of our analyses with those from previous GRNs.

MATERIALS AND METHODS

In this work we study the *P. aeruginosa* CCBH4851 strain, which is deposited at the Culture Collection of Hospital-Acquired Bacteria (CCBH) located at the Laboratório de Pesquisa em Infecção Hospitalar, Instituto Oswaldo Cruz/Fundação Oswaldo Cruz (Fiocruz) (WDCM947; 39 CGEN022/2010). The genome sequence is available in the GenBank database (Accession CP021380.2).⁽¹⁴⁾

CCBH-2019 and PAO1-2020 were the bases for the reconstruction of this GRN. CCBH-2022 results from the orthology analysis between the *P. aeruginosa* PAO1 and CCBH4851 gene sequences. The CCBH-2022 model also inherits the orthologs between CCBH4851 and *P. aeruginosa* PA7⁽²¹⁾ and *P. aeruginosa* PA14⁽²²⁾ strains, which were already present in CCBH-2019.

The evolutionary histories of genes and species reconstruction are based critically on the accurate identification of orthologs.⁽²³⁾ Orthology refers to a specific relationship between homologous characters that arose by speciation at their most recent point of origin,^(24,25) a common ancestor.

One of the most common approaches to determine orthology in comparative genomics is the Reciprocal Best Hits (RBH), which BLAST relies on.⁽²⁶⁾ An RBH occurs when two genes, each in a different genome, find themselves as the best scoring match in the opposite genome.^(27, 28)

Regulatory interactions between TFs and TGs in the PAO1 GRN were propagated to the CCBH-2022 GRN if the TF and the TG formed a RBH.

An algorithm was designed and implemented by Medeiros *et al.*⁽²⁾ using the Python programming language to automate and generate a list of RBHs in a tabular format (available as Supplementary Data). All the protein sequences from *P. aeruginosa* CCBH4851 (P1) and *P. aeruginosa* PAO1 (P2) were considered. BLAST+ ⁽²⁹⁾ were used to query the proteins from P1 against those from P2 (forward results) and P2 against P1 (reverse results). Each P1's query sequence was considered in turns, and its best match from P2 was identified from forwarding results (x). Likewise, each P2's query sequence was considered from the reverse results, with its best match in P1 (x'). If $x = x'$, then they are RBH. Local BLASTP searches of each protein set against the other were executed, with the following cut-off parameters: *identity* $\geq 90\%$, *coverage* $\geq 90\%$, and *E-value* $\leq 1 \text{ e-}5$, showing the results in tabular format.

If the search returned no hits, the gene was considered to have no ortholog within the opposite genome. Manual BLASTP was used to prevent false negatives, aligning these gene sequences with the opposite genome, considering the above parameters. If they still returned no hits but were present in either PAO1-2020 or CCBH-2019, the results were evaluated with a literature search to determine if they were accurate and whether they should or not be part of the CCBH-2022. The final GRN table is available as Supplementary data and is organized into six columns: Regulatory gene, Ortholog of the regulatory gene, Target gene, Ortholog of the target gene, Mode of regulation, and Reference. The first column lists the regulatory genes of *P. aeruginosa* CCBH4851 while the second column contains orthologs of regulatory genes in the reference strain (PAO1 and PA7 or

PA14 from the exclusive interactions in CCBH-2019; the same applies to TG's orthologs). The third column refers to the target gene in *P. aeruginosa* CCBH4851 while the fourth column lists orthologs of TGs in the reference strain. The fifth column describes the mode of regulation and the sixth column indicates the source of the corresponding data.

The set of interactions between transcription factor proteins and the genes that they regulate in an organism define a directed graph.

For the computational analysis, the structure of GRN can be represented as a directed graph, formed by a set of vertices (or nodes) connected by a set of directed edges (or links). Basic network measurements are related to vertex connectivity, occurrence of cycles, and the distances between pairs of nodes, among other possibilities.⁽³⁰⁾

The degree of vertices is the most elementary characterization of a node, being the $k(i)$ defined as its number of edges. In directed networks, there are incoming (k -in degree) edges and outgoing (k -out degree) edges.⁽³¹⁾ The degree distribution can follow a functional form $P(k) = Ak^{-\gamma}$, called power-law distribution, where $P(k)$ is the likelihood that a randomly chosen node from the network has k direct interactions, A is a constant that ensures that the $P(k)$ values add up to one, and γ is the degree exponente.⁽³²⁻³⁶⁾ According to Albert (2005),⁽³⁷⁾ this function indicates high diversity of node degrees, with the $P(k)$ value decaying as a power law that is free of a characteristic scale, resulting in the absence of a typical node in the network that could be used to characterize the rest of the nodes. Most real networks with structural information available exhibit this scale-free behavior, deviating from a Poisson distribution expected in a classical random network.^(38,39)

Studies have shown a scale-free structure in cellular metabolic networks,^(32,40) protein interaction networks, including in cancer,^(41,42) transcription regulatory networks, and GRN.^(20,43-45)

Following the literature,^(36,37,46-48) there is some qualitative and quantitative characteristics to ensure that a network is scale-free: the power-law distribution appears as a straight line on a logarithmic plot; the γ value usually is in the range $2 < \gamma < 3$; and the presence of high-degree nodes, called hubs, dominating the network, with most nodes clustered around them.

The hubs show the absence of a uniform connectivity distribution in the network, presenting the 70-30 rule (also referred to as the Pareto principle), with small-degree nodes being the most abundant. However, the frequency of high-degree nodes decreases slowly.⁽³⁷⁾ Hubs are fundamental for determining therapeutic targets against an infectious agent.⁽²⁾

Scale-free networks are heterogeneous,⁽⁴⁹⁾ so random node disruptions (the 70%) do not lead to a significant loss of connectivity. However, the loss of the hubs (the 30%) causes the breakdown of the network into isolated clusters.⁽⁵⁰⁾

Some studies validate these general conclusions for cellular networks.⁽⁵¹⁻⁵³⁾

In the GRN, determining the vertices with the highest k-out degrees is a method for identifying a hub,⁽²⁾ The degree threshold is the exact number of interactions that characterize a hub, and this criteria differs from a study to another.⁽⁵⁴⁾ The degree threshold adopted in this work was the average number of connections of all nodes having at least two edges, resulting in a cut-off value of 16 connections. Motifs are patterns of connectivity, a small set of recurring regulation patterns from which the networks are built ^(55,56) that are associated with specific functions.⁽⁵⁷⁾ A triangle, i.e., three fully connected vertices, is the minimum of a

motif.⁽⁴⁷⁾ These genes are a regulator, X, which regulates Y, and gene Z, which is regulated by both X and Y.⁽⁵⁸⁾ Triangles can be closed (three connections within the set) or open (two edges).⁽³⁸⁾ This 3-genes motif is the feedforward loop (FFL), and the most common in GRN, appearing in gene systems in bacteria and other organisms,^(59,60) with the possibility of either activation and repression in each of the three regulatory interactions.⁽⁶¹⁾ The coherent type-1 FFL and the incoherent type-1 FFL occur more frequently in transcriptional networks.⁽⁵⁸⁾

The clustering coefficient is the probability that two genes with a common neighbor in a graph are also interconnected.⁽¹⁹⁾ There are two popular definitions of this measure: the local and global clustering coefficient.

The local clustering coefficient of vertex i , C_i , is defined as $C_i = 2e_i / k_i (k_i - 1)$, where e_i is the number of edges connecting node i with degree k_i , and $k_i (k_i - 1) / 2$ is the maximum number of edges in the neighborhood of node i .⁽³⁶⁾ In GRNs, the local clustering coefficient $C(i)$ is interpreted as the interaction between genes forming the regulatory groups.⁽²⁾

The clustering coefficient of a network, C , is calculated by the average of C_i over all vertices.^(19,62)

Not considering the directionality of the edges, the global clustering coefficient is the ratio between the number of closed triangles and the total number of triangles (open or closed) in the network.⁽²⁾

$C(k)$ represents the mean clustering coefficient over the vertices with degree k .⁽³⁶⁾

Some biological networks tend to present high clustering coefficient values.⁽⁴⁷⁾

The network density measure is the number of edges of the network over the maximum possible number of edges, measuring the interconnectivity between

vertices, and is strongly correlated to the potential to generate gene expression heterogeneity.⁽⁶³⁾

The network diameter is the path length between the two most distant nodes.⁽³⁶⁾

The average path length is the measure that indicates the distances between pairs of vertices (the average of the shortest path length over all pairs of nodes in the network).⁽⁴⁶⁾

Several genes are connected with one another in the GRN. When the nodes interact through a direct or an indirect link (intermediate connections), they are considered as a part of a connected component. These associations are the concept of network connectivity, and for this analysis in the present work, network interactions were considered undirected.⁽²⁾

Analyzing the structural characteristics (connected components, hubs, and motifs) can help determine the best approach to disturb a network to promote a desired phenotype in the cell.⁽⁶⁴⁾

For the CCBH-2022 structural analyses, the R programming language and RStudio were used.⁽⁶⁵⁾ Scales, dplyr, tibble, readr and igraph packages were used for data manipulation and plotting of the structural analyses.^(2,20,66) The igraph library was used to compute most of the properties described above: the in and out degrees, centrality, clustering coefficients, feed-forward loop motifs, connectivity, cycles, paths, and hierarchical levels analyses.⁽⁶⁷⁾

The illustrations of the GRN, the hub's network and the connectivity analysis were made in Cytoscape.⁽⁶⁸⁾ All figures are presented with higher resolution in the Supplementary Material.

The Supplementary Data, the codes for the structural analysis in R and for finding RBH in python, implemented by Medeiros *et al.*⁽²⁾, and the CCBH-2022 file in CSV

format are available in our Github repository (<https://github.com/FioSysBio/CCBH2022>).

RESULTS:


The CCBH-2022 consists of 5507 regulatory interactions among 3291 gene products, of which 217 were identified as regulatory genes and 3071 as target genes. Of the 217 regulatory proteins, 87 are TFs, 19 are sigma factors (SF), and 13 are RNAs. Of these 13 RNAs, 11 are SF as well. The tables containing their relations are present in the Supplementary Material.

Given the 6577 predicted protein-coding genes of *P. aeruginosa* CCBH4851, the model organism in this study, the current network represents roughly 50% of the genome, against 16.52% from CCBH-2019.

Specific regulatory genes and their interactions were kept as described in the CCBH-2019, such as the ones resulting from the *P. aeruginosa* PA7 and *P. aeruginosa* PA14 orthology, and in dedicated biological databases and scientific literature, e.g., IHF (integration host factor). This bacterial DNA-bending protein, essential in gene expression regulation, is absent in the CCBH4851 genome. However Delic-Attree *et al.* (1995)⁽⁶⁹⁾ demonstrated that *P. aeruginosa* contains the IHF protein composed of the products of the *himA* and *himD* genes. These genes act in combination as a TF for several TGs,⁽²⁾ and all were listed as regulatory genes in CCBH-2019. Consequently, equivalent notations to the previous CCBH4851 GRN were maintained.

CCBH-2022 has 5507 edges, and these interactions were classified into activation (“+”), repression (“-”), dual (“d”, when, depending on the conditions, the regulatory gene act as an activator or a repressor), and unknown (“?”). An illustration of CCBH-2022 is presented in Fig.1.

A



B







Fig.1: visualization of the CCBH-2022. Yellow circles indicate regulatory genes, light blue circles indicate target genes, black lines indicate an unknown mode of regulation, green lines indicate

activation, and red lines indicate repression. Purple lines indicate a dual-mode of regulation. A: the GRN large highly connected network component; B: all regulatory and TGs with no connections with A.








Fig. 2: graphical representation of structural measurements of the CCBH-2022 (red) compared to the previously published networks: PAO1-2011 (purple), CCBH-2019 (orange), and PAO1-2020 (green). **A, B**: incoming degree distribution of the four GRNs; **C, D**: outgoing distribution of the

four GRNs. The distributions are plotted on a linear (A, C) and on a logarithmic scale (B, D); **E**: local clustering coefficient distribution; **F**: clustering coefficient by degree.

Regarding the structural measurements of the updated network, the summarized statistical results are presented in Table 1. It contains the standard measures (the number of nodes and edges, number of autoregulatory motifs, network diameter, and average path length), the number of feed-forward motifs, and clustering coefficients. Also, Table I presents a comparison with data from the PAO1-2011, CCBH-2019, PAO1-2020, and CCBH-2022.

TABLE I
Comparison of structural statistic measures between the PAO1-2011, CCBH-2019, PAO1-2020, CCBH-2022

	PAO1-2011	CCBH-2019	PAO1-2020	CCBH-2022
Vertices	690	1046	3006	3291
Edges	1020	1576	5040	5507
Regulatory genes	76	138	173	217
Target genes	593	908	2709	3071
Positive regulation	779	772	3851	3873
Negative regulation	218	454	390	661
Dual regulation	11	13	10	16
Unknown regulation	12	337	789	957
Autoregulation (total)	29	72	50	93
Positive autoregulation	16	21	24	30
Negative autoregulation	13	39	15	46
Unknown autoregulation	-	12	11	17
Feed-forward loop motifs (total) α	137	208	702	951
Coherent type I feed-forward loop motifs α	82	79	226	240
Incoherent type II feed-forward loop motifs α	3	4	8	10
Density	2.12e-03	1.44e-03	6.07e-04	5.68e-04
Diameter	9	12	12	12
Average shortest path length	04.08	4.80	04.01	4.65
Global clustering coefficient	2.28e-02	3.2e-02	3.03e-03	4.27e-03
Local clustering coefficient	2.5e-01	1.92e-01	1.63e-01	1.89e-01

α : number of feed-forward loop motifs determined using the igraph package.

The CCBH-2022 had a density of $5.68e-04$, much higher than PAO1-2011 ($2.12e-03$) and CCBH-2019's ($1.44e-03$) densities. It was slightly lower than the density of PAO1-2020 ($6.07e-04$) but showed the same order of magnitude.

The diameter was 12, the same as the CCBH-2019 and PAO1-2020 and higher than PAO1-2011, which was 9.

The average shortest path distance was 4.65, higher than PAO1-2020 (4.01) but slightly lower than CCBH-2019 (4.80).

The degree distributions of the four networks can be seen in Fig. 2 (A, B, C, D), with A and B being the incoming and C and D the outgoing degree distribution. Fig. 2B, D is on a double logarithmic axis and the straight line is consistent with a power-law distribution. For k-in, the estimated value for γ was 2.79, within the range $2 < \gamma < 3$, consistent with a power law distribution. For the PAO1-2020 GRN the corresponding value was 2.67, being 2.89 for the CCBH-2019 GRN and 2.71 for the PAO1-2011 GRN.

The distribution of local clustering coefficients can be seen in Fig. 2E.

The CCBH-2022 had a global clustering coefficient equal to $4.27e-03$, higher than previous networks (PAO1-2020: $3.03e-03$; CCBH-2019: $3.2e-02$; PAO1-2011: $2.28e-02$).

The scatter plot in Fig. 2F shows the correlation between the local clustering coefficient $C(i)$ and the degree $k(i)$.

Similar to the previous GRN, CCBH-2022 was disconnected, showing one large connected component (3034 genes) and 26 small connected components.

The most frequent mode of regulation in CCBH-2022 is activation, being 70,3% of the total interactions in the network, followed by 12% of repression mode and 17.6% of dual or unknown mode. Autoregulation occurs when a gene regulates

its own expression, and the prevalence in the CCBH-2022 is of negative autoregulatory motifs.

The most abundant motif in all four networks was the coherent type I FFL, with 240 in the CCBH-2022 (PAO1-2011: 82; CCBH-2019: 79; PAO1-2020: 226). In addition, there were ten incoherent type II FFL motifs in the CCBH-2022 (PAO1-2011: 3; CCBH-2019: 4; PAO1-2020: 8).

Table II shows the 30 most influential hubs in the CCBH-2022.

TABLE II
The 30 most influential hubs of the CCBH-2022

Gene	Total number of connections (k-out)	Function
<i>rpoD</i>	740	Control of expression of housekeeping genes ⁷⁰
<i>rpoN</i>	665	Nitrogen metabolism, adhesion, quorum sensing (QS), biofilm formation ⁷¹
<i>algU</i>	353	Positive regulation of response to oxidative stress ⁷²
<i>sigX</i>	298	Positive regulation of cell growth ⁷³
<i>rpoS</i>	279	QS, Biofilm, virulence, antibiotic resistance ⁷⁴
<i>fliA</i>	272	Adhesion, flagellin biosynthesis ⁷⁵
<i>rpoH</i>	185	Heat-shock response ⁷⁶
<i>gacA</i>	121	Monolayer and biofilm formation ⁷⁷
<i>algR</i>	119	Cell motility, biofilm formation ⁷⁸
<i>lasR</i>	116	QS, regulation of elastin catabolic process ⁷⁹
<i>amrZ</i>	109	Cell motility, biofilm formation ⁸⁰
<i>fur</i>	93	Control of expression of siderophores and exotoxin A ⁸¹
<i>pvdS</i>	93	Iron metabolism, pyoverdine, virulence ^{82, 83}
<i>fleQ</i>	92	Regulation of mucin adhesion and flagellar expression. ⁸⁴
<i>sphR</i>	74	Sphingosine catabolic process ⁸⁵
<i>mvfR</i>	65	QS, regulation of lyase activity, control production of virulence factors ⁸⁶
<i>vqsM</i>	62	QS, control production of virulence factors ⁸⁷

<i>mexT</i>	58	Antibiotic efflux pump ⁸⁸
<i>anr</i>	58	Regulation of oxidoreductase activity ⁸⁹
<i>rhIR</i>	56	QS, regulation of lipid biosynthetic and proteolysis ^{90, 91}
<i>pchR</i>	47	Regulation of pyochelin siderophore, ferripyochelin receptor synthesis ⁹²
<i>argR</i>	46	Controls arginine uptake and metabolism ⁹³
<i>pmrA</i>	43	Antibiotic efflux pump ^{94, 95}
<i>fecl</i>	41	Regulation of iron ion transport ⁹⁶
<i>soxR</i>	40	Antibiotic efflux pump ⁹⁷
<i>phoB</i>	40	Cell motility, regulation of cellular response to phosphate starvation ^{98, 99}
<i>gbdR</i>	39	Regulation of cellular amino acid metabolic process ¹⁰⁰
<i>vfr</i>	37	QS, exotoxin A regulator, cell motility ¹⁰¹
<i>dnr</i>	36	Regulation of nitrogen compound metabolic process ¹⁰²
<i>phoP</i>	34	Antibiotic efflux pump ¹⁰³

An analysis was performed to determine whether the hubs are interconnected through direct interactions (Fig.3).




Fig.3: connectivity relationships among the 30 most influential hubs of the CCBH-2022. Yellow circles indicate regulatory genes considered hubs, light blue circles indicate target genes, black lines indicate an unknown mode of regulation, green lines indicate activation, and red lines indicate repression. Purple lines indicate a dual-mode of regulation.

DISCUSSION:

As one of the most important networks of bacteria described in the literature, the GRN of *P. aeruginosa* reconstruction and analysis contributes to giving a better understanding of its antibiotic resistance and for the knowledge of related cellular processes, such as adaptive and pathogenic, mainly when based on an MDR strain as CCBH4851.

In this work, we have good coverage of roughly 50% of the genome on this updated network. The genome of reference strain PAO1 has 6.2Mbp, and the PAO1-2020 has a coverage of 50% as well, with 5040 interactions and 3006 genes.⁽²⁰⁾ However, considering that the CCBH4851 genome has 6.8Mbp and has 5507 edges, and 3291 nodes, we can affirm that, to the best of our knowledge, this study presents the largest GRN of *P. aeruginosa* that has been assembled to date.

On the structural aspects, the charts in Fig.2 and data in Table I make clear that CCBH-2022 represents a substantial improvement in terms of network completeness and complexity when compared with the previous *P. aeruginosa* GRNs, since it includes more nodes, edges, and network motifs, and when comparing clustering coefficients (Fig. 2E, F). For the *in silico* approach, the network structural analysis is essential to understand the network architecture and performance.

The structural measures of the CCBH-2022, such as node degree distribution and clustering coefficient, are consistent with a qualitative description of a scale-free network type. Indeed, the degree distribution followed the power-law distribution (Fig. 2B, D): a small number of nodes had many connections (the hubs) and many nodes had few connections.

The local clustering coefficient and node degree correlation (Fig. 2F) showed that nodes with lower degrees had greater local clustering coefficients than nodes with higher degrees. These characteristics are representative of several biological processes, e.g., RNA binding.^(104,105)

The CCBH-2022 showed a lower density value than PAO1-2020. The density of both GRNs was low due to the dynamic and structural flexibility of the networks,

a characteristic typical of natural phenomena-based networks (106), and because the nodes were not all interconnected.⁽²⁾ However, CCBH-2022 density was lower probably because it has 26 small connected components disconnected from the larger one (Fig.1), while the PAO1-2020 had 12 separated components. The variation in the number of connected components is plausible due to their size difference and the biological information about interactions available for the reconstruction.

All the previous *P. aeruginosa* GRNs are disconnected, showing one large connected component and a separated few small connected components, and there may be several reasons for this disconnection in specific points. According to Medeiros *et al.*⁽²⁾, interactions among all genes are not really expected since some genes in an organism are independent of each other, compartmentalized or global, constitutive or growth phase-dependent, and are triggered in different growth phases, thus resulting in a disconnected network, which corroborates with the observed low density. The reason can also be from loss of existing interactions or a gain of interactions still not fully described from additional strain-specific blocks of genes acquired by horizontal gene transfer.⁽¹⁰⁷⁾

The large number of connected components found in the CCBH-2022 GRN results from connectivity parameters and the global clustering coefficient. Both structural measures are affected by the same biological behaviors.⁽¹⁰⁶⁾

The most frequent regulatory activity in CCBH-2022 is activation, but ~50% of the autoregulation was negative, which may be a consequence of the increase in negative regulation in the overall network interactions compared to the previous ones. Negative auto-regulation in biological systems is commonly observed.⁽¹⁰⁸⁾

The *Escherichia coli* GRN exhibited the same pattern, with the negative

autoregulation prevailing concurrently with the positive regulation in the overall network.⁽¹⁰⁹⁾ The continuity of biological processes is ensured by positive autoregulation.⁽¹¹⁰⁾ For example, quorum sensing, biofilm formation, secretion of toxins, virulence and resistance factors production, once initiated, must reach a final stage in order to have the expected effect.⁽²⁾ In the CCBH-2022 GRN, genes involved in these processes, such as *lasR*,⁽⁷⁹⁾ *rlhR*,⁽⁹¹⁾ *pvdS*,⁽⁸³⁾ *algU*,⁽⁷²⁾ *dnr*⁽¹⁰²⁾ and *anr*,⁽⁸⁹⁾ have positive autoregulation (and are hubs).

Negative cycles are also crucial for life-sustaining cyclic processes such as metabolic processes⁽¹¹¹⁾ and cellular homeostasis.⁽¹¹²⁾ In the CCBH-2022 GRN, genes involved in arginine metabolism (*iscR*, *desT*, *lexA*, *hutC*, and *mvat*)⁽¹⁰⁹⁾ showed a predominance of negative mode of autoregulation. Negative autoregulation is associated with cellular stability.⁽¹¹³⁾ It provides a rapid response to variations in concentrations of proteins, toxins and (or) metabolites, to avoid undesired effects such as energy cost of unneeded synthesis.⁽¹¹⁴⁾ In the CCBH-2022 GRN, *algZ* (transcriptional activator of AlgD, involved in alginate production),⁽¹¹⁵⁾ *lexA* (involved in the SOS response),⁽¹¹⁶⁾ *metR* (involved in swarming motility and methionine synthesis),^(117,118) *ptxR* (affects exotoxin A production)⁽¹¹⁹⁾ and *rsaL* (quorum-sensing repressor)⁽¹²⁰⁾ presented negative autoregulatory interactions. Autoregulation is common among genes positioned upstream in GRN with crucial developmental functions.^(121,122)

The FFL motifs are essential for the modulation of cellular processes according to environmental conditions.⁽¹²³⁾ CCBH-2022 has 951 FFL motifs, which are patterns of structural structures, while the PAO1-2020 has 702. There are 240 coherent type I FFL motifs in the CCBH-2022, an abundant presence. According to Mangan & Alon (2003)⁽¹²⁴⁾ these motifs act as sign-sensitive delay elements

i.e., a circuit that responds rapidly to steplike stimuli in one direction (ON to OFF), and as a delay to steps in the opposite direction (OFF to ON); the temporary removal of the stimulus ceases transcription, so the activation of expression requires a persistent signal to carry on.

The incoherent type II FFL motif was less represented but also found in all the GRN, with a total of 10 in the CCBH-2022 GRN. Contrastingly with the coherent FFL, the type II FFL acts as a sign-sensitive accelerator, i.e., a circuit that responds rapidly to step-like stimuli in one direction but not in the other direction.⁽¹²⁴⁾

One last characteristic revealed by the structural analysis was the presence of hubs. The hub's network (Fig. 3) shows the connection among their interactions; they are all interconnected, and belong to the largest connected component of the GRN (Fig.1A).

This connectivity reflects the importance of the influential genes. The hubs can be considered the basis of the GRN. They are crucial in searching for potential drug targets for developing new drugs, as in a direct interaction with their specific targets or as for an indirect interaction with the subsequent process regulation triggered by them. The CCBH-2022 hubs are mainly associated with efflux pump mechanisms (*mexT*, *pmrA*, *soxR*, *phoP*),^(88,94,97,103) alginate biosynthesis (*algU*, *algR*, *rpoN*),⁽¹²⁵⁾ and biofilm formation (*rpoN*, *rpoS*, *gacA*, *amrZ*).⁽¹²⁶⁾

Table III shows the 30 hubs of PAO1-2020.

TABLE III
The 30 most influential hubs in the PAO1-2020

Gene	Total number of connections (k-out)
<i>rpoD</i>	749
<i>rpoN</i>	658
<i>algU</i>	357

<i>sigX</i>	319
<i>fliA</i>	281
<i>rpoS</i>	271
<i>rpoH</i>	194
<i>gacA</i>	128
<i>algR</i>	122
<i>amrZ</i>	115
<i>lasR</i>	95
<i>pvdS</i>	91
<i>sphR</i>	90
<i>fleQ</i>	85
<i>fur</i>	69
<i>vqsM</i>	65
<i>mvfR</i>	62
<i>pchR</i>	57
<i>anr</i>	53
<i>mexT</i>	51
<i>argR</i>	46
<i>fecl</i>	44
<i>gbdR</i>	42
<i>rhIR</i>	40
<i>phoB</i>	40
<i>pmrA</i>	40
<i>soxR</i>	39
<i>dnr</i>	34
<i>himA</i>	30
<i>himD</i>	30

They are overly similar to the CCBH-2022 hubs, with some changes in the k-out connections. However, two CCBH-2022 hubs were not present in PAO1-2020: *vrf*, a global virulence factor regulator ⁽¹²⁷⁾ that directly regulates 37 genes, and *phoP*, associated with multidrug-resistance, including polymyxin,^(128,129) which directly regulates 34 genes. These facts strongly indicate that the operation of the main network hubs is not identical. The functioning of CCBH4851 is different given the presence of these 2 critical genes associated with multi-drug resistance mechanisms.

The *Vfr* gene's role in regulation of virulence factor production is related to the production of exotoxin A, a toxin that modifies specific target proteins within mammalian cells and induces necrosis in different tissues and organs in MDR *P. aeruginosa* infections.^(130,131) The *Vfr* gene also regulates the *las* and consequently the *rhl* quorum-sensing system, two systems that together control expression of several genes associated with virulence factor production,⁽¹³²⁾ including alkaline protease, exotoxin A, pyocyanin, and rhamnolipid, as well as critical genes such as *rpoS* (the 5th most influential gene in CCBH-2022).⁽¹³³⁾ The signal receptor (*R* gene) is one of the essential components of the *las* and *rhl* QS systems. It is necessary for coding the transcriptional activator protein (*R* protein).⁽¹³⁴⁾ The *lasR* and *rhlR* genes are among the 20 principal hubs.

The *phoP* gene has an essential role in MDR *P. aeruginosa*, being involved in more than one drug-resistant mechanism. Apart from their role in two-component regulatory systems with *phoQ* gene, it also plays significant roles in multidrug efflux pumps and alteration in drug targets.⁽¹³⁵⁾ Miller *et al.* (2011)⁽¹²⁸⁾ showed that deletion of the *phoPQ* two-component regulatory system locus in a laboratory-adapted *P. aeruginosa* PAK, which is considered an MDR strain, resulted in loss of polymyxin resistance.⁽¹³⁶⁾

P. aeruginosa evades the antimicrobial activity during treatment and exerts antimicrobial resistance by mainly intrinsic resistance mechanisms. Examples of resistance mechanisms are multi-drug efflux pumps, biofilm synthesis, enzymatic inactivation/degradation, drug permeability restriction, production of beta-lactamases, acquired resistance by a mutation in drug targets, and acquisition of resistance genes via horizontal gene transfer.⁽¹³⁵⁾

There is a directed regulatory connection from alginate biosynthesis to iron metabolism and some antibiotic resistance mechanisms.⁽¹³⁷⁾ The *algU*, *algR*, *rpoN*, *pvdS* and *fecI* genes are related to these processes^(138,139) and are among the most influential hubs.

P. aeruginosa has multiple efflux pump systems that prevent the antimicrobial agents from accumulating in adequate concentration to cause an effect in the cell, extruding the drug out.⁽¹³⁵⁾ Efflux pump systems are associated with resistance to beta-lactams, fluoroquinolones, tetracycline, chloramphenicol, macrolides, and aminoglycosides.⁽¹⁴⁰⁾ Differential expression or mutations of efflux system genes are also contributing factors for both carbapenem and aminoglycoside resistance.⁽¹⁴¹⁾ The *mexT*, *pmrA*, *soxR* genes, related to multidrug antibiotic efflux pumps, are also amongst the most influential hubs.

The *fleQ* gene is also among the hubs and affects *psl* (polysaccharide synthesis locus) genes and the regulation of the efflux pump genes, *mexA*, *mexE*, and *oprH*, by *brlR*.^(2,142) The *psl* cluster comprises 15 exopolysaccharide biosynthesis-related genes organized in tandem that are important for biofilm formation.⁽¹⁴³⁾

The *mexT* and *soxR* genes positively regulate an efflux pump system and several virulence factors,^(144,145) and *pmrA* regulates efflux pumps and the polymyxin B and colistin resistance.^(95,146,147)

Efflux pumps also help biofilm formation.⁽¹⁴⁸⁾ Biofilms are also related to protection from the host immune system and antibiotic penetration and tolerance, preventing them from entering the microbial population, inhibiting its action as a first-line defense mechanism.^(123,149,150)

The *rpoN*, *rpoS*, *gacA*, *algR* and *amrZ* hubs participate in the regulation of *P. aeruginosa* biofilm.

This system biology approach to characterize the MDR *P. aeruginosa* CCBH4851 regulatory network may lead to the development of strategies to disrupt the connectivity of these essential processes, thus, possibly decreasing the pathogenicity and suppressing the resistance of this bacterium.

CONCLUSIONS:

This manuscript reports the reconstruction and structural analysis of the largest *P. aeruginosa* regulatory network to date.

This work can give new insights into identifying novel candidate antibiotic targets and contributes to an increase in our understanding of the behavior of this bacterium.

This network's dynamic model construction is one of our future studies, intending to help researchers working on experimental drug design and screening. The goal is to predict the dynamic behavior better and improve the understanding of *P. aeruginosa*, allowing the simulation of normal and stress conditions to discover potential therapeutic targets and help develop new drugs against *P. aeruginosa*'s bacterial infection.

ACKNOWLEDGEMENTS:

To Inova-Fiocruz (grant #VPPCB-007-FIO-18-2-117), Faperj and Capes, for financial support.

AUTHOR'S CONTRIBUTIONS:

MSC performed the GRN reconstruction, its visualization and drafted the manuscript. FMF performed the structural analysis. FABS supervised this study. FMF, MTS, MAM, APDCA and FABS provided scientific advice and contributed to revision of the text. All authors read and approved the final manuscript.

CONFLICTS OF INTEREST:

The authors declare that they have no competing interests.

REFERENCES:

1. Montero MM, López Montesinos I, Knobel H, Molas E, Sorlí L, Siverio-Parés A, Prim N, Segura C, Duran-Jordà X, Grau S, Horcajada JP. Risk Factors for Mortality among Patients with *Pseudomonas aeruginosa* Bloodstream Infections: What Is the Influence of XDR Phenotype on Outcomes? *J Clin Med*. 2020 Feb 14;9(2):514. doi: 10.3390/jcm9020514.
2. Medeiros Filho F, do Nascimento APB, Dos Santos MT, Carvalho-Assef APD, da Silva FAB. Gene regulatory network inference and analysis of multidrug-resistant *Pseudomonas aeruginosa*. *Mem Inst Oswaldo Cruz*. 2019;114:e190105. doi: 10.1590/0074-02760190105.
3. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, Benito N, Grau S. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa* Infections. *Clin Microbiol Rev*. 2019 Aug 28;32(4):e00031-19. doi: 10.1128/CMR.00031-19.
4. Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, Powers JH 3rd, Suffredini AF, Hooper DC, Fridkin S, Danner RL; National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH-ARORI). Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. *Clin Infect Dis*. 2018 Nov 28;67(12):1803-1814. doi: 10.1093/cid/ciy378.
5. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β -lactamase Producing *Enterobacterales* (ESBL-E), Carbapenem-Resistant *Enterobacterales* (CRE), and *Pseudomonas aeruginosa* with Difficult-to-Treat Resistance (DTR-P. *aeruginosa*). *Clin Infect Dis*. 2021 Apr 8;72(7):e169-e183. doi: 10.1093/cid/ciaa1478.
6. Matos ECO, Andriolo RB, Rodrigues YC, Lima PDL, Carneiro ICDRS, Lima KVB. Mortality in patients with multidrug-resistant *Pseudomonas aeruginosa* infections: a meta-analysis. *Rev Soc Bras Med Trop*. 2018 Jul-Aug;51(4):415-420. doi: 10.1590/0037-8682-0506-2017.
7. Haque M, Sartelli M, McKimm J, Abu Bakar M. Health care-associated infections - an overview. *Infect Drug Resist*. 2018 Nov 15;11:2321-2333. doi: 10.2147/IDR.S177247.
8. Litwin A, Rojek S, Gozdzik W, Duszyńska W. *Pseudomonas aeruginosa* device associated - healthcare associated infections and its multidrug resistance at intensive care unit of University Hospital: polish, 8.5-

year, prospective, single-centre study. *BMC Infect Dis*. 2021 Feb 16;21(1):180. doi: 10.1186/s12879-021-05883-5.

9. Agência Nacional de Vigilância Sanitária. Boletim Segurança do Paciente e Qualidade em Serviços de Saúde nº23. Avaliação dos indicadores nacionais das Infecções Relacionadas à Assistência à Saúde (IRAS) e Resistência microbiana do ano de 2020 [Internet]. Brasília, DF: Anvisa; 2020 [cited 2022 April 24]. Available from:

<https://app.powerbi.com/view?r=eyJrljoiZGI3NzEwMmYtMDI1Yy00ZDE1LWI0YzItY2NiNDdmODZjZDgzliwidCI6ImI2N2FmMjNmLWmzZjMtNGQzNS04MGM3LWI3MDg1ZjVIZGQ4MSJ9&pageName=ReportSectionac5c0437dbe709793b4b>

10. Yang P, Chen Y, Jiang S, Shen P, Lu X, Xiao Y. Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014. *Antimicrob Resist Infect Control*. 2018 Nov 19;7:137. doi: 10.1186/s13756-018-0430-1. 11. Martins WMBS, Narciso AC, Cayô R, Santos SV, Fehlberg LCC, Ramos PL, da Cruz JB, Gales AC. SPM-1-producing *Pseudomonas aeruginosa* ST277 clone recovered from microbiota of migratory birds. *Diagn Microbiol Infect Dis*. 2018 Mar;90(3):221-227. doi: 10.1016/j.diagmicrobio.2017.11.003.

12. Nascimento AP, Ortiz MF, Martins WM, Morais GL, Fehlberg LC, Almeida LG, Ciapina LP, Gales AC, Vasconcelos AT. Intraclonal Genome Stability of the Metallo- β -lactamase SPM-1-producing *Pseudomonas aeruginosa* ST277, an Endemic Clone Disseminated in Brazilian Hospitals. *Front Microbiol*. 2016 Dec 5;7:1946. doi: 10.3389/fmicb.2016.01946.

13. Toleman MA, Simm AM, Murphy TA, Gales AC, Biedenbach DJ, Jones RN, Walsh TR. Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. *J Antimicrob Chemother*. 2002 Nov;50(5):673-9. doi: 10.1093/jac/dfk210.

14. Silveira M, Albano R, Asensi M, Assef AP. The draft genome sequence of multidrug-resistant *Pseudomonas aeruginosa* strain CCBH4851, a nosocomial isolate belonging to clone SP (ST277) that is prevalent in Brazil. *Mem Inst Oswaldo Cruz*. 2014 Dec;109(8):1086-7. doi: 10.1590/0074-0276140336.

15. Kitano H. Computational systems biology. *Nature*. 2002 Nov 14;420(6912):206-10. doi: 10.1038/nature01254.

16. Bryce D, Kim S. Planning for Gene Regulatory Network Intervention. November 2010 ACM Transactions on Intelligent Systems and Technology 1(2):11. doi: 10.1145/1869397.1869400.

17. Ryall KA, Tan AC. Systems biology approaches for advancing the discovery of effective drug combinations. *J Cheminform*. 2015 Feb 26;7:7. doi: 10.1186/s13321-015-0055-9.

18. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warren P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrook-Wadman S, Yuan Y, Brody LL, Coulter

- SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV. Complete genome sequence of *Pseudomonas aeruginosa* PAO1, an opportunistic pathogen. *Nature*. 2000 Aug 31;406(6799):959-64. doi: 10.1038/35023079.
19. Galán-Vásquez E, Luna B, Martínez-Antonio A. The Regulatory Network of *Pseudomonas aeruginosa*. *Microb Inform Exp*. 2011 Jun 14;1(1):3. doi: 10.1186/2042-5783-1-3.
20. Galán-Vásquez E, Luna-Olivera BC, Ramírez-Ibáñez M, Martínez-Antonio A. RegulomePA: a database of transcriptional regulatory interactions in *Pseudomonas aeruginosa* PAO1. *Database (Oxford)*. 2020 Dec 1;2020:baaa106. doi: 10.1093/database/baaa106.
21. Roy PH, Tetu SG, Larouche A, Elbourne L, Tremblay S, Ren Q, Dodson R, Harkins D, Shay R, Watkins K, Mahamoud Y, Paulsen IT. Complete genome sequence of the multiresistant taxonomic outlier *Pseudomonas aeruginosa* PA7. *PLoS One*. 2010 Jan 22;5(1):e8842. doi: 10.1371/journal.pone.0008842.
22. Lee DG, Urbach JM, Wu G, Liberati NT, Feinbaum RL, Miyata S, Diggins LT, He J, Saucier M, Déziel E, Friedman L, Li L, Grills G, Montgomery K, Kucherlapati R, Rahme LG, Ausubel FM. Genomic analysis reveals that *Pseudomonas aeruginosa* virulence is combinatorial. *Genome Biol*. 2006;7(10):R90. doi: 10.1186/gb-2006-7-10-r90.
23. Tekaia F, Yeramian E. SuperPartitions: detection and classification of orthologs. *Gene*. 2012 Jan 15;492(1):199-211. doi: 10.1016/j.gene.2011.10.027.
24. Fitch WM. Distinguishing homologous from analogous proteins. *Syst Zool*. 1970 Jun;19(2):99-113.
25. Fitch WM. Homology a personal view on some of the problems. *Trends Genet*. 2000 May;16(5):227-31. doi: 10.1016/s0168-9525(00)02005-9.
26. Hernández-Salmerón JE, Moreno-Hagelsieb G. Progress in quickly finding orthologs as reciprocal best hits: comparing blast, last, diamond and MMseqs2. *BMC Genomics*. 2020 Oct 24;21(1):741. doi: 10.1186/s12864-020-07132-6.
27. Overbeek R, Fonstein M, D'Souza M, Pusch GD, Maltsev N. The use of gene clusters to infer functional coupling. *Proc Natl Acad Sci U S A*. 1999 Mar 16;96(6):2896-901. doi: 10.1073/pnas.96.6.2896.
28. Ward N, Moreno-Hagelsieb G. Quickly finding orthologs as reciprocal best hits with BLAT, LAST, and UBLAST: how much do we miss? *PLoS One*. 2014 Jul 11;9(7):e101850. doi: 10.1371/journal.pone.0101850.
29. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. BLAST+: architecture and applications. *BMC Bioinformatics*. 2009 Dec 15;10:421. doi: 10.1186/1471-2105-10-421.
30. da F. Costa L, Rodrigues FA, Travieso G, Boas PRV. Characterization of Complex Networks: A Survey of measurements. *Advances in Physics* 56. 2007 167;242. 10.1080/00018730601170527.

31. Bazanella AS, Gevers M, Hendrickx JM, Parraga A. Identifiability of dynamical networks: which nodes need be measured? 2017 IEEE 56th Annual Conference on Decision and Control (CDC). 2017 Dec. doi:10.1109/CDC.2017.8264547.
32. Jeong H, Tombor B, Albert R, Oltvai ZN, Barabási AL. The large-scale organization of metabolic networks. *Nature*. 2000 Oct 5;407(6804):651-4. doi: 10.1038/35036627.
33. Dorogovtsev SN, Mendes JF. Scaling properties of scale-free evolving networks: continuous approach. *Phys Rev E Stat Nonlin Soft Matter Phys*. 2001 May;63(5 Pt 2):056125. doi: 10.1103/PhysRevE.63.056125.
34. Strogatz SH. Exploring complex networks. *Nature*. 2001 Mar 8;410(6825):268-76. doi: 10.1038/35065725.
35. Girvan M, Newman ME. Community structure in social and biological networks. *Proc Natl Acad Sci U S A*. 2002 Jun 11;99(12):7821-6. doi: 10.1073/pnas.122653799.
36. Almaas E, Barabási AL. Power Laws in Biological Networks. *In: Koonin EV, Wolf YI, Karev GP. Power Laws, Scale-free Networks and Genome Biology*. 2006. 1-9.
37. Albert R. Scale-free networks in cell biology. *J Cell Sci*. 2005 Nov 1;118(Pt 21):4947-57. doi: 10.1242/jcs.02714.
38. Barabási AL, Oltvai ZN. Network biology: understanding the cell's functional organization. *Nat Rev Genet*. 2004 Feb;5(2):101-13. doi: 10.1038/nrg1272.
39. Pastor-Satorras R, Vespignani A. *Evolution and Structure of the Internet: A Statistical Physics Approach*. Cambridge: Cambridge University Press. 2004. doi:10.1017/CBO9780511610905
40. Rajula HSR, Mauri M, Fanos V. Scale-free networks in metabolomics. *Bioinformatics*. 2018 Mar 31;14(3):140-144. doi: 10.6026/97320630014140.
41. Nacher JC, Hayashida M, Akutsu T. Emergence of scale-free distribution in protein-protein interaction networks based on random selection of interacting domain pairs. *Biosystems*. 2009 Feb;95(2):155-9. doi: 10.1016/j.biosystems.2008.10.002.
42. Chen AX, Zopf CJ, Mettetal J, Shyu WC, Bolen J, Chakravarty A, Palani S. Scale-free structure of cancer networks and their vulnerability to hub-directed combination therapy. 2020. doi: 10.1101/2020.07.01.159657.
43. Wolf IR, Simões RP, Valente GT. Three topological features of regulatory networks control life-essential and specialized subsystems. *Sci Rep*. 2021 Dec 20;11(1):24209. doi: 10.1038/s41598-021-03625-w.
44. Farkas IJ, Jeong H, Vicsek T, Barabási AL, Oltvai ZN. The topology of the transcription regulatory network in the yeast, *S. cerevisiae*. *Physica A: Statistical Mechanics and its Applications* 318(3-4):601-612. 2003. DOI:10.1016/S0378-4371(02)01731-4.

45. Abdelzaher AF, Al-Musawi AF, Ghosh P, Mayo ML, Perkins EJ. Transcriptional Network Growing Models Using Motif-Based Preferential Attachment. *Front Bioeng Biotechnol.* 2015 Oct 12;3:157. doi: 10.3389/fbioe.2015.00157.
46. Arita M. The metabolic world of *Escherichia coli* is not small. *Proc Natl Acad Sci U S A.* 2004 Feb 10;101(6):1543-7. doi: 10.1073/pnas.0306458101.
47. da F. Costa L, Rodrigues FA, Cristino AS. Complex networks: The key to systems biology. *Genetics and Molecular Biology.* 2008. 31. 10.1590/S1415-47572008000400001.
48. Barabási AL. *Linked: How Everything Is Connected to Everything Else and What It Means for Business, Science, and Everyday Life.* 2014. 105pp.
49. Liu Z, Lai YC, Ye N. Propagation and immunization of infection on general networks with both homogeneous and heterogeneous components. *Physical review. E, Statistical, nonlinear, and soft matter physics.* 2003. 67. 031911. 10.1103/PhysRevE.67.031911.
50. Albert R, Barabasi AL. *Statistical Mechanics Of Complex Networks.* *Reviews of Modern Physics.* 2001. 74. 10.1103/RevModPhys.74.47.
51. Jeong H, Mason SP, Barabási AL, Oltvai ZN. Lethality and centrality in protein networks. *Nature* 2001;411:41–2. <https://doi.org/10.1038/35075138>.
52. Said MR, Begley TJ, Oppenheim AV, Lauffenburger DA, Samson LD. Global network analysis of phenotypic effects: protein networks and toxicity modulation in *Saccharomyces cerevisiae*. *Proc Natl Acad Sci U S A.* 2004 Dec 28;101(52):18006-11. doi: 10.1073/pnas.0405996101.
53. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. *Nature.* 2000 Nov 16;408(6810):307-10. doi: 10.1038/35042675.
54. Vandereyken K, Van Leene J, De Coninck B, Cammue BPA. Hub Protein Controversy: Taking a Closer Look at Plant Stress Response Hubs. *Front Plant Sci.* 2018 Jun 5;9:694. doi: 10.3389/fpls.2018.00694.
55. Milo R, Shen-Orr S, Itzkovitz S, Kashtan N, Chklovskii D, Alon U. Network motifs: simple building blocks of complex networks. *Science.* 2002 Oct 25;298(5594):824-7. doi: 10.1126/science.298.5594.824.
56. Shen-Orr SS, Milo R, Mangan S, Alon U. Network motifs in the transcriptional regulation network of *Escherichia coli*. *Nat Genet.* 2002 May;31(1):64-8. doi: 10.1038/ng881.
57. Wuchty S, Oltvai ZN, Barabási AL. Evolutionary conservation of motif constituents in the yeast protein interaction network. *Nat Genet.* 2003 Oct;35(2):176-9. doi: 10.1038/ng1242.
58. Alon U. Network motifs: theory and experimental approaches. *Nat Rev Genet.* 2007 Jun;8(6):450-61. doi: 10.1038/nrg2102.
59. Ma HW, Kumar B, Ditzges U, Gunzer F, Buer J, Zeng AP. An extended transcriptional regulatory network of *Escherichia coli* and analysis of its hierarchical structure and network motifs. *Nucleic Acids Res.* 2004 Dec 16;32(22):6643-9. doi: 10.1093/nar/gkh1009.

60. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, Young RA. Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell*. 2005 Sep 23;122(6):947-56. doi: 10.1016/j.cell.2005.08.020.
61. Mangan S, Alon U. Structure and function of the feed-forward loop network motif. *Proc Natl Acad Sci U S A*. 2003 Oct 14;100(21):11980-5. doi: 10.1073/pnas.2133841100.
62. Prokhorenkova LO & Samosvat E. Global Clustering Coefficient in Scale-Free Networks. 2014. 10.1007/978-3-319-13123-8_5.
63. Bouyioukos C & Kim J. Gene Regulatory Network Properties Linked to Gene Expression Dynamics in Spatially Extended Systems. 5777. 321-328. 2009. DOI: 10.1007/978-3-642-21283-3_40.
64. Burda Z, Krzywicki A, Martin OC, Zagorski M. Motifs emerge from function in model gene regulatory networks. *Proc Natl Acad Sci U S A*. 2011 Oct 18;108(42):17263-8. doi: 10.1073/pnas.1109435108.
65. RStudio Team (2020). RStudio: Integrated Development for R. RStudio, PBC, Boston, MA Available from <http://www.rstudio.com/>.
66. Ramos TG. Reconstrução da Rede Metabólica da *Pseudomonas aeruginosa* CCBH4851. 2018 [cited 2022 Mar 12]; Available from: <https://www.arca.fiocruz.br/handle/icict/29528>.
67. Csardi G, Nepusz T. The Igraph Software Package for Complex Network Research. *InterJournal, Complex Systems 2006, 1695 (5): 1-9*.
68. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res*. 2003 Nov;13(11):2498-504. doi: 10.1101/gr.1239303.
69. Delic-Attree I, Toussaint B, Vignais PM. Cloning and sequence analyses of the genes coding for the integration host factor (IHF) and HU proteins of *Pseudomonas aeruginosa*. *Gene*. 1995 Feb 27;154(1):61-4. doi: 10.1016/0378-1119(94)00875-s.
70. Aramaki H, Fujita M. In vitro transcription analysis of rpoD in *Pseudomonas aeruginosa* PAO1. *FEMS Microbiol Lett*. 1999 Nov 15;180(2):311-6. doi: 10.1111/j.1574-6968.1999.tb08811.x.
71. Caiazza NC, O'Toole GA. SadB is required for the transition from reversible to irreversible attachment during biofilm formation by *Pseudomonas aeruginosa* PA14. *J Bacteriol*. 2004 Jul;186(14):4476-85. doi: 10.1128/JB.186.14.4476-4485.2004.
72. Martin DW, Schurr MJ, Yu H, Deretic V. Analysis of promoters controlled by the putative sigma factor AlgU regulating conversion to mucoidy in *Pseudomonas aeruginosa*: relationship to sigma E and stress response. *J Bacteriol*. 1994 Nov;176(21):6688-96. doi: 10.1128/jb.176.21.6688-6696.1994.
73. Brinkman FS, Schoofs G, Hancock RE, De Mot R. Influence of a putative ECF sigma factor on expression of the major outer membrane protein, OprF, in *Pseudomonas aeruginosa* and *Pseudomonas fluorescens*. *J Bacteriol*. 1999 Aug;181(16):4746-54. doi: 10.1128/JB.181.16.4746-4754.1999.

74. Fujita M, Tanaka K, Takahashi H, Amemura A. Transcription of the principal sigma-factor genes, *rpoD* and *rpoS*, in *Pseudomonas aeruginosa* is controlled according to the growth phase. *Mol Microbiol.* 1994 Sep;13(6):1071-7. doi: 10.1111/j.1365-2958.1994.tb00498.x.
75. Starnbach MN, Lory S. The *fliA* (*rpoF*) gene of *Pseudomonas aeruginosa* encodes an alternative sigma factor required for flagellin synthesis. *Mol Microbiol.* 1992 Feb;6(4):459-69. doi: 10.1111/j.1365-2958.1992.tb01490.x.
76. Benvenisti L, Koby S, Rutman A, Giladi H, Yura T, Oppenheim AB. Cloning and primary sequence of the *rpoH* gene from *Pseudomonas aeruginosa*. *Gene.* 1995 Mar 21;155(1):73-6. doi: 10.1016/0378-1119(94)00829-h.
77. Parkins MD, Ceri H, Storey DG. *Pseudomonas aeruginosa* *GacA*, a factor in multihost virulence, is also essential for biofilm formation. *Mol Microbiol.* 2001 Jun;40(5):1215-26. doi: 10.1046/j.1365-2958.2001.02469.x.
78. Lizewski SE, Lundberg DS, Schurr MJ. The transcriptional regulator AlgR is essential for *Pseudomonas aeruginosa* pathogenesis. *Infect Immun.* 2002 Nov;70(11):6083-93. doi: 10.1128/IAI.70.11.6083-6093.2002.
79. Gambello MJ, Iglewski BH. Cloning and characterization of the *Pseudomonas aeruginosa* *lasR* gene, a transcriptional activator of elastase expression. *J Bacteriol.* 1991 May;173(9):3000-9. doi: 10.1128/jb.173.9.3000-3009.1991.
80. Waligora EA, Ramsey DM, Pryor EE Jr, Lu H, Hollis T, Sloan GP, Deora R, Wozniak DJ. AmrZ beta-sheet residues are essential for DNA binding and transcriptional control of *Pseudomonas aeruginosa* virulence genes. *J Bacteriol.* 2010 Oct;192(20):5390-401. doi: 10.1128/JB.00711-10.
81. Barton HA, Johnson Z, Cox CD, Vasil AI, Vasil ML. Ferric uptake regulator mutants of *Pseudomonas aeruginosa* with distinct alterations in the iron-dependent repression of exotoxin A and siderophores in aerobic and microaerobic environments. *Mol Microbiol.* 1996 Sep;21(5):1001-17. doi: 10.1046/j.1365-2958.1996.381426.x.
82. Cunliffe HE, Merriman TR, Lamont IL. Cloning and characterization of *pvdS*, a gene required for pyoverdine synthesis in *Pseudomonas aeruginosa*: *PvdS* is probably an alternative sigma factor. *J Bacteriol.* 1995 May;177(10):2744-50. doi: 10.1128/jb.177.10.2744-2750.1995.
83. Beare PA, For RJ, Martin LW, Lamont IL. Siderophore-mediated cell signalling in *Pseudomonas aeruginosa*: divergent pathways regulate virulence factor production and siderophore receptor synthesis. *Mol Microbiol.* 2003 Jan;47(1):195-207. doi: 10.1046/j.1365-2958.2003.03288.x.
84. Arora SK, Ritchings BW, Almira EC, Lory S, Ramphal R. A transcriptional activator, *FleQ*, regulates mucin adhesion and flagellar gene expression in *Pseudomonas aeruginosa* in a cascade manner. *J Bacteriol.* 1997 Sep;179(17):5574-81. doi: 10.1128/jb.179.17.5574-5581.1997.

85. LaBauve AE, Wargo MJ. Detection of host-derived sphingosine by *Pseudomonas aeruginosa* is important for survival in the murine lung. *PLoS Pathog.* 2014 Jan;10(1):e1003889. doi: 10.1371/journal.ppat.1003889.
86. Déziel E, Gopalan S, Tampakaki AP, Lépine F, Padfield KE, Saucier M, Xiao G, Rahme LG. The contribution of MvfR to *Pseudomonas aeruginosa* pathogenesis and quorum sensing circuitry regulation: multiple quorum sensing-regulated genes are modulated without affecting lasRI, rhlRI or the production of N-acyl-L-homoserine lactones. *Mol Microbiol.* 2005 Feb;55(4):998-1014. doi: 10.1111/j.1365-2958.2004.04448.x.
87. Liang H, Deng X, Li X, Ye Y, Wu M. Molecular mechanisms of master regulator VqsM mediating quorum-sensing and antibiotic resistance in *Pseudomonas aeruginosa*. *Nucleic Acids Res.* 2014;42(16):10307-20. doi: 10.1093/nar/gku586.
88. Köhler T, Epp SF, Curty LK, Pechère JC. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of *Pseudomonas aeruginosa*. *J Bacteriol.* 1999 Oct;181(20):6300-5. doi: 10.1128/JB.181.20.6300-6305.1999.
89. Rompf A, Hungerer C, Hoffmann T, Lindenmeyer M, Römling U, Gross U, Doss MO, Arai H, Igarashi Y, Jahn D. Regulation of *Pseudomonas aeruginosa* hemF and hemN by the dual action of the redox response regulators Anr and Dnr. *Mol Microbiol.* 1998 Aug;29(4):985-97. doi: 10.1046/j.1365-2958.1998.00980.x.
90. Ochsner UA, Koch AK, Fiechter A, Reiser J. Isolation and characterization of a regulatory gene affecting rhamnolipid biosurfactant synthesis in *Pseudomonas aeruginosa*. *J Bacteriol.* 1994 Apr;176(7):2044-54. doi: 10.1128/jb.176.7.2044-2054.1994.
91. Brint JM, Ohman DE. Synthesis of multiple exoproducts in *Pseudomonas aeruginosa* is under the control of RhIR-RhII, another set of regulators in strain PAO1 with homology to the autoinducer-responsive LuxR-LuxI family. *J Bacteriol.* 1995 Dec;177(24):7155-63. doi: 10.1128/jb.177.24.7155-7163.1995.
92. Heinrichs DE, Poole K. Cloning and sequence analysis of a gene (pchR) encoding an AraC family activator of pyochelin and ferripyochelin receptor synthesis in *Pseudomonas aeruginosa*. *J Bacteriol.* 1993 Sep;175(18):5882-9. doi: 10.1128/jb.175.18.5882-5889.1993.
93. Lu CD, Yang Z, Li W. Transcriptome analysis of the ArgR regulon in *Pseudomonas aeruginosa*. *J Bacteriol.* 2004 Jun;186(12):3855-61. doi: 10.1128/JB.186.12.3855-3861.2004.
94. Piddock LJ, Johnson MM, Simjee S, Pumbwe L. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 2002 Mar;46(3):808-12. doi: 10.1128/AAC.46.3.808-812.2002.
95. McPhee JB, Lewenza S, Hancock RE. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides

- in *Pseudomonas aeruginosa*. Mol Microbiol. 2003 Oct;50(1):205-17. doi: 10.1046/j.1365-2958.2003.03673.x.
96. Miyazaki H, Kato H, Nakazawa T, Tsuda M. A positive regulatory gene, pvdS, for expression of pyoverdinin biosynthetic genes in *Pseudomonas aeruginosa* PAO. Mol Gen Genet. 1995 Jul 22;248(1):17-24. doi: 10.1007/BF02456609.
97. Palma M, Zurita J, Ferreras JA, Worgall S, Larone DH, Shi L, Campagne F, Quadri LE. *Pseudomonas aeruginosa* SoxR does not conform to the archetypal paradigm for SoxR-dependent regulation of the bacterial oxidative stress adaptive response. Infect Immun. 2005 May;73(5):2958-66. doi: 10.1128/IAI.73.5.2958-2966.2005.
98. Faure LM, Llamas MA, Bastiaansen KC, de Bentzmann S, Bigot S. Phosphate starvation relayed by PhoB activates the expression of the *Pseudomonas aeruginosa* σ rel ECF factor and its target genes. Microbiology (Reading). 2013 Jul;159(Pt 7):1315-1327. doi: 10.1099/mic.0.067645-0.
99. Blus-Kadosh I, Zilka A, Yerushalmi G, Banin E. The effect of pstS and phoB on quorum sensing and swarming motility in *Pseudomonas aeruginosa*. PLoS One. 2013 Sep 4;8(9):e74444. doi: 10.1371/journal.pone.0074444.
100. Wargo MJ, Ho TC, Gross MJ, Whittaker LA, Hogan DA. GbdR regulates *Pseudomonas aeruginosa* plcH and pchP transcription in response to choline catabolites. Infect Immun. 2009 Mar;77(3):1103-11. doi: 10.1128/IAI.01008-08.
101. Beatson SA, Whitchurch CB, Sargent JL, Levesque RC, Mattick JS. Differential regulation of twitching motility and elastase production by Vfr in *Pseudomonas aeruginosa*. J Bacteriol. 2002 Jul;184(13):3605-13. doi: 10.1128/JB.184.13.3605-3613.2002.
102. Trunk K, Benkert B, Quäck N, Münch R, Scheer M, Garbe J, Jänsch L, Trost M, Wehland J, Buer J, Jahn M, Schobert M, Jahn D. Anaerobic adaptation in *Pseudomonas aeruginosa*: definition of the Anr and Dnr regulons. Environ Microbiol. 2010 Jun;12(6):1719-33. doi: 10.1111/j.1462-2920.2010.02252.x.
103. Lee JY, Ko KS. Mutations and expression of PmrAB and PhoPQ related with colistin resistance in *Pseudomonas aeruginosa* clinical isolates. Diagn Microbiol Infect Dis. 2014 Mar;78(3):271-6. doi: 10.1016/j.diagmicrobio.2013.11.027.
104. Zhu X, Gerstein M, Snyder M. Getting connected: analysis and principles of biological networks. Genes Dev. 2007; 21(9): 1010-24.
105. Hao D, Li C. The dichotomy in degree correlation of biological networks. PLoS One. 2011;6(12):e28322. doi: 10.1371/journal.pone.0028322.
106. Bales ME, Johnson SB. Graph theoretic modeling of large-scale semantic networks. J Biomed Inform. 2006 Aug;39(4):451-64. doi: 10.1016/j.jbi.2005.10.007.

107. Mathee K, Narasimhan G, Valdes C, Qiu X, Matewish JM, Koehrsen M, Rokas A, Yandava CN, Engels R, Zeng E, Olavarietta R, Doud M, Smith RS, Montgomery P, White JR, Godfrey PA, Kodira C, Birren B, Galagan JE, Lory S. Dynamics of *Pseudomonas aeruginosa* genome evolution. *Proc Natl Acad Sci U S A*. 2008 Feb 26;105(8):3100-5. doi: 10.1073/pnas.0711982105.
108. Madar D, Dekel E, Bren A, Alon U. Negative auto-regulation increases the input dynamic-range of the arabinose system of *Escherichia coli*. *BMC Syst Biol*. 2011 Jul 12;5:111. doi: 10.1186/1752-0509-5-111.
109. Martínez-Antonio A, Janga SC, Thieffry D. Functional organisation of *Escherichia coli* transcriptional regulatory network. *J Mol Biol*. 2008 Aug 1;381(1):238-47. doi: 10.1016/j.jmb.2008.05.054.
110. Adhya S, Garges S. Positive control. *J Biol Chem*. 1990 Jul 5;265(19):10797-800.
111. Shaw K. Negative transcription regulation in prokaryotes. *Nature Education*. 2008. 1(1):122.
112. Ferrell JE Jr. Feedback loops and reciprocal regulation: recurring motifs in the systems biology of the cell cycle. *Curr Opin Cell Biol*. 2013 Dec;25(6):676-86. doi: 10.1016/j.ceb.2013.07.007.
113. Becskei A, Serrano L. Engineering stability in gene networks by autoregulation. *Nature*. 2000 Jun 1;405(6786):590-3. doi: 10.1038/35014651.
114. Nevozhay D, Adams RM, Murphy KF, Josic K, Balázsi G. Negative autoregulation linearizes the dose-response and suppresses the heterogeneity of gene expression. *Proc Natl Acad Sci U S A*. 2009 Mar 31;106(13):5123-8. doi: 10.1073/pnas.0809901106.
115. Baynham PJ, Wozniak DJ. Identification and characterization of AlgZ, an AlgT-dependent DNA-binding protein required for *Pseudomonas aeruginosa* algD transcription. *Mol Microbiol*. 1996 Oct;22(1):97-108. doi: 10.1111/j.1365-2958.1996.tb02659.x.
116. Cirz RT, O'Neill BM, Hammond JA, Head SR, Romesberg FE. Defining the *Pseudomonas aeruginosa* SOS response and its role in the global response to the antibiotic ciprofloxacin. *J Bacteriol*. 2006 Oct;188(20):7101-10. doi: 10.1128/JB.00807-06.
117. Maxon ME, Redfield B, Cai XY, Shoeman R, Fujita K, Fisher W, Stauffer G, Weissbach H, Brot N. Regulation of methionine synthesis in *Escherichia coli*: effect of the MetR protein on the expression of the metE and metR genes. *Proc Natl Acad Sci U S A*. 1989 Jan;86(1):85-9. doi: 10.1073/pnas.86.1.85.
118. Yeung AT, Torfs EC, Jamshidi F, Bains M, Wiegand I, Hancock RE, Overhage J. Swarming of *Pseudomonas aeruginosa* is controlled by a broad spectrum of transcriptional regulators, including MetR. *J Bacteriol*. 2009 Sep;191(18):5592-602. doi: 10.1128/JB.00157-09.
119. Hamood AN, Colmer JA, Ochsner UA, Vasil ML. Isolation and characterization of a *Pseudomonas aeruginosa* gene, ptxR, which positively regulates exotoxin A production. *Mol Microbiol*. 1996 Jul;21(1):97-110. doi: 10.1046/j.1365-2958.1996.6251337.x.
120. Rampioni G, Schuster M, Greenberg EP, Bertani I, Grasso M, Venturi V, Zennaro E, Leoni L. RsaL provides quorum sensing homeostasis and functions as a global regulator of gene expression in

Pseudomonas aeruginosa. Mol Microbiol. 2007 Dec;66(6):1557-65. doi: 10.1111/j.1365-2958.2007.06029.x.

121. Crews ST, Pearson JC. Transcriptional autoregulation in development. Curr Biol. 2009 Mar 24;19(6):R241-6. doi: 10.1016/j.cub.2009.01.015.

122. Hoot SJ, Brown RP, Oliver BG, White TC. The UPC2 promoter in *Candida albicans* contains two cis-acting elements that bind directly to Upc2p, resulting in transcriptional autoregulation. Eukaryot Cell. 2010 Sep;9(9):1354-62. doi: 10.1128/EC.00130-10.

123. Zhang Q, Bhattacharya S, Conolly RB, Clewell HJ, Kaminski NE, Andersen ME. Molecular signaling network motifs provide a mechanistic basis for cellular threshold responses. Environ Health Perspect. 2014 Dec;122(12):1261-70. doi: 10.1289/ehp.1408244.

124. Mangan S, Alon U. Structure and function of the feed-forward loop network motif. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):11980-5. doi: 10.1073/pnas.2133841100.

125. Zielinski NA, Maharaj R, Roychoudhury S, Danganan CE, Hendrickson W, Chakrabarty AM. Alginate synthesis in *Pseudomonas aeruginosa*: environmental regulation of the algC promoter. J Bacteriol. 1992 Dec;174(23):7680-8. doi: 10.1128/jb.174.23.7680-7688.1992.

126. Anupama R, Mukherjee A, Babu S. Gene-centric metegenome analysis reveals diversity of *Pseudomonas aeruginosa* biofilm gene orthologs in fresh water ecosystem. Genomics. 2018 Mar;110(2):89-97. doi: 10.1016/j.ygeno.2017.08.010.

127. Blier AS, Veron W, Bazire A, Gerault E, Taupin L, Vieillard J, Rehel K, Dufour A, Le Derf F, Orange N, Hulen C, Feuilloley MGJ, Lesouhaitier O. C-type natriuretic peptide modulates quorum sensing molecule and toxin production in *Pseudomonas aeruginosa*. Microbiology (Reading). 2011 Jul;157(Pt 7):1929-1944. doi: 10.1099/mic.0.046755-0.

128. Miller AK, Brannon MK, Stevens L, Johansen HK, Selgrade SE, Miller SI, Høiby N, Moskowitz SM. PhoQ mutations promote lipid A modification and polymyxin resistance of *Pseudomonas aeruginosa* found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother. 2011 Dec;55(12):5761-9. doi: 10.1128/AAC.05391-11.

129. Behzadi P, Baráth Z, Gajdács M. It's Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant *Pseudomonas aeruginosa*. Antibiotics (Basel). 2021 Jan 4;10(1):42. doi: 10.3390/antibiotics10010042.

130. Runyen-Janecky LJ, Albus AM, Iglewski BH, West SEH. The transcriptional activator Vfr binds to two apparently different binding sites in the promoters of *Pseudomonas aeruginosa* virulence genes. In: 96th General Meeting of the American Society for Microbiology. New Orleans, LA. 1996.

131. Coppola PE, Gaibani P, Sartor C, Ambretti S, Lewis RE, Sassi C, Pignatti M, Paolini S, Curti A, Castagnetti F, Ursi M, Cavo M, Stanzani M. Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug

Resistant *Pseudomonas aeruginosa* Infections in Neutropenic Patients. *Microorganisms*. 2020 Dec 21;8(12):2055. doi: 10.3390/microorganisms8122055.

132. Suh SJ, Runyen-Janecky LJ, Maleniak TC, Hager P, MacGregor CH, Zielinski-Mozny NA, Phibbs PV, West SEH. Effect of *vfr* mutation on global gene expression and catabolite repression control of *Pseudomonas aeruginosa*. *Microbiology (Reading)*. 2002 May;148(Pt 5):1561-1569. doi: 10.1099/00221287-148-5-1561.

133. Glessner A, Smith RS, Iglewski BH, Robinson JB. Roles of *Pseudomonas aeruginosa* *las* and *rhl* quorum-sensing systems in control of twitching motility. *J Bacteriol*. 1999 Mar;181(5):1623-9. doi: 10.1128/JB.181.5.1623-1629.1999.

134. İnat G, Sırken B, Başkan C, Erol İ, Yıldırım T, Çiftci A. Quorum sensing systems and related virulence factors in *Pseudomonas aeruginosa* isolated from chicken meat and ground beef. *Sci Rep*. 2021 Aug 2;11(1):15639. doi: 10.1038/s41598-021-94906-x.

135. Miryala SK, Anbarasu A, Ramaiah S. Systems biology studies in *Pseudomonas aeruginosa* PA01 to understand their role in biofilm formation and multidrug efflux pumps. *Microb Pathog*. 2019 Nov;136:103668. doi: 10.1016/j.micpath.2019.103668.

136. Hraiech S, Brégeon F, Rolain JM. Bacteriophage-based therapy in cystic fibrosis-associated *Pseudomonas aeruginosa* infections: rationale and current status. *Drug Des Devel Ther*. 2015 Jul 16;9:3653-63. doi: 10.2147/DDDT.S53123.

137. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and alternative therapeutic strategies. *Biotechnol Adv*. 2019 Jan-Feb;37(1):177-192. doi: 10.1016/j.biotechadv.2018.11.013.

138. Hay ID, Wang Y, Moradali MF, Rehman ZU, Rehm BH. Genetics and regulation of bacterial alginate production. *Environ Microbiol*. 2014 Oct;16(10):2997-3011. doi: 10.1111/1462-2920.12389.

139. Leoni L, Orsi N, de Lorenzo V, Visca P. Functional analysis of PvdS, an iron starvation sigma factor of *Pseudomonas aeruginosa*. *J Bacteriol*. 2000 Mar;182(6):1481-91. doi: 10.1128/JB.182.6.1481-1491.2000.

140. Tenover FC. Mechanisms of Antimicrobial Resistance in Bacteria. *The American Journal of Medicine*. 2006. 119(6):3-10. doi: 10.1016/j.amjmed.2006.03.011.

141. Jo JT, Brinkman FS, Hancock RE. Aminoglycoside efflux in *Pseudomonas aeruginosa*: involvement of novel outer membrane proteins. *Antimicrob Agents Chemother*. 2003 Mar;47(3):1101-11. doi: 10.1128/AAC.47.3.1101-1111.2003.

142. Baraquet C, Harwood CS. FleQ DNA Binding Consensus Sequence Revealed by Studies of FleQ-Dependent Regulation of Biofilm Gene Expression in *Pseudomonas aeruginosa*. *J Bacteriol*. 2015 Oct 19;198(1):178-86. doi: 10.1128/JB.00539-15.

143. Zegans ME, Wozniak D, Griffin E, Toutain-Kidd CM, Hammond JH, Garfoot A, Lam JS. *Pseudomonas aeruginosa* exopolysaccharide Psl promotes resistance to the biofilm inhibitor polysorbate 80. *Antimicrob Agents Chemother*. 2012 Aug;56(8):4112-22. doi: 10.1128/AAC.00373-12.
144. Maseda H, Saito K, Nakajima A, Nakae T. Variation of the mexT gene, a regulator of the MexEF-oprN efflux pump expression in wild-type strains of *Pseudomonas aeruginosa*. *FEMS Microbiol Lett*. 2000 Nov 1;192(1):107-12. doi: 10.1111/j.1574-6968.2000.tb09367.x.
145. Sakhtah H, Koyama L, Zhang Y, Morales DK, Fields BL, Price-Whelan A, Hogan DA, Shepard K, Dietrich LE. The *Pseudomonas aeruginosa* efflux pump MexGHI-OpmD transports a natural phenazine that controls gene expression and biofilm development. *Proc Natl Acad Sci U S A*. 2016 Jun 21;113(25):E3538-47. doi: 10.1073/pnas.1600424113.
146. Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. *J Antimicrob Chemother*. 2003 Jan;51(1):9-11. doi: 10.1093/jac/dkg050.
147. Lee JY, Ko KS. Mutations and expression of PmrAB and PhoPQ related with colistin resistance in *Pseudomonas aeruginosa* clinical isolates. *Diagn Microbiol Infect Dis*. 2014 Mar;78(3):271-6. doi: 10.1016/j.diagmicrobio.2013.11.027.
148. Alav I, Sutton JM, Rahman KM. Role of bacterial efflux pumps in biofilm formation. *J Antimicrob Chemother*. 2018 Aug 1;73(8):2003-2020. doi: 10.1093/jac/dky042.
149. Leid JG. Bacterial biofilms resist key host defenses. *Microbe* 2009;4(2):66-70.
150. Zhang Q, Bhattacharya S, Conolly RB, Clewell HJ, Kaminski NE, Andersen ME. Molecular signaling network motifs provide a mechanistic basis for cellular threshold responses. *Environ Health Perspect*. 2014 Dec;122(12):1261-70. doi: 10.1289/ehp.1408244.